An interventional study of Exercise and meal testing (acute stimuli) in Pregnancy in Diabetic and Type 1 Diabetes, sponsored by University of Graz. Completed at 1 site in Austria. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by University of Graz · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Poor glycaemic control in pregnancy is a major factor leading to obstetric complications and future maternal-offspring diseases. This phenomenon is evidenced in women with type 1 diabetes (T1DM), and is worrisome since it is aggravating the disease burden of this and next generations.
Exercise is a promising tool to improve glucose control during pregnancy and thus avoid adverse consequences.
The MERIT1D study will explore when is exercise (before or after lunch) more effective to improve postprandial glycaemic control in pregnant and non-pregnant women (of reproductive age) with T1DM, and the mechanisms underlying these metabolic responses.
Poor glycaemic control in pregnancy is a major factor leading to obstetric complications and future maternal-offspring diseases (e.g., macrosomia, diabetes). This phenomenon is evidenced in women with type 1 diabetes (T1DM), and is worrisome since it is aggravating the disease burden of this and next generations. Therefore, to find strategies aimed at breaking this intergenerational cycle has become a high-priority. Exercise is a promising tool to improve short-term glycaemic responses such as postprandial glucose peaks and glucose variability, and thus reduce adverse maternal-neonatal outcomes. However, it is unknown which timing of exercise is more effective to optimise postprandial glycaemic control in pregnant women with T1DM, and non-pregnant women (of reproductive age) with T1DM. The mechanisms underlying these benefits in T1DM and pregnancy are also to be established.
The MERIT1D project will unravel which timing of exercise (before or after a meal at lunchtime) is more effective to optimise postprandial glycaemic control in pregnant and non-pregnant women with T1DM, and the mechanisms underlying these metabolic responses. Ten pregnant women with T1DM and ten non-pregnant women with T1DM will be involved in this randomised controlled crossover trial.
Pregnant women at gestational week 16 and 35 (experimental phases 1 and 2, respectively), and non-pregnant peers once after recruitment (experimental phase 1), will undergo 3 experimental conditions within 10 days (random order): pre-meal exercise, post-meal exercise, and non-exercise meal.
Each experimental phase will entail participants attending 4 times to the research centre. Therefore, pregnant women will come to the research centre for a total of 8 study visits, while non-pregnant women will come only to 4 study visits. The acute exercise stimulus will consist of a well-controlled submaximal walking test. The standardised meal provided will consist of a mixed milkshake equivalent to the 35 % of their resting energy expenditure, being made up of approximately 45% carbohydrates, 35% fat, and 20% proteins. Postprandial glycaemic responses will be continuously monitored using last-generation glucose monitoring systems during the 10-day period. Immunometabolic markers (e.g., lipids, cytokines) will be determined in maternal blood and placenta samples.
The MERIT1D study will contribute to the understanding of exercise timing in T1DM and pregnancy, and its underlying mechanisms. This will translate into a better clinical prediction, diagnosis, prognosis and treatment of glycaemic dysregulations, and into more effective exercise programmes for pregnant and non-pregnant women with T1DM.
46 studies on the registry are indexed under Pregnancy in Diabetics; 16 are open to participants now.
This study's enrollment of 20 is below the median of 95 across 24 interventional studies indexed under Pregnancy in Diabetics.
Browse Pregnancy in Diabetics studies →University of Graz is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo 3 experimental conditions in random order at week of gestation 16 and 35 (experimental phases 1 and 2): pre-meal exercise, post-meal exercise, and non-exercise meal.
Other: Exercise and meal testing (acute stimuli)
Participants will undergo 3 experimental conditions in random order after recruitment (experimental phase 1): pre-meal exercise, post-meal exercise, and non-exercise meal.
Other: Exercise and meal testing (acute stimuli)
Pre-meal exercise: 1º milkshake intake + 2º exercise test Post-meal exercise: 1º exercise test + 2º milkshake intake Non-exercise meal: Only milkshake intake
Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition
* T1DM non-pregnant women, euglycemic range: 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women, euglycemic range: 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition
* T1DM non-pregnant women: 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women: 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Percentage of time spent in hypoglycemia for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Percentage of time spent in hypoglycemia for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Percentage of time spent in hyperglycemia for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Percentage of time spent in hyperglycemia for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Differences in postprandial glucose levels 1-, 2-, and 4-hours post-experiment
Within-change in glucose values (mmol/L) from pre-experiment (before starting exercise/meal testing) to post-experiment (i.e., 1-, 2-, and 4-hours after starting exercise/meal intake) in each experimental day
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 4 h/day)
Differences in postprandial glucose levels 1-, 2-, and 4-hours post-experiment
Within-change in glucose values (mmol/L) from pre-experiment (before starting exercise/meal testing) to post-experiment (i.e., 1-, 2-, and 4-hours after starting exercise/meal intake) in each experimental day
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 4 h/day)
Number of hypoglycaemic events for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Number of hypoglycaemic events for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Number of hyperglycaemic events for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Number of hyperglycaemic events for the 24 hours after each experimental condition
* T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Percentage of time spent in nocturnal euglycemia within each experimental day
* T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 00:00 am - 05:59 am)
Percentage of time spent in nocturnal euglycemia within each experimental day
* T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 00:00 am - 05:59 am )
Percentage of time spent in diurnal euglycemia within each experimental day
* T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 6.00 am - 23:59 am)
Percentage of time spent in diurnal euglycemia within each experimental day
* T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 6.00 am - 23:59 am)
Area under the curve of glycaemic exposure
Area under the curve of glycaemic exposure during the 2, 4 and 8 hours after meal intake at each experimental condition.
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 8 hours/day)
Area under the curve of glycaemic exposure
Area under the curve of glycaemic exposure during the 2, 4 and 8 hours after meal intake at each experimental condition.
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 8 h/day)
Glycaemic variability (standard deviation)
Standard deviation (SD) of the mean continuous glucose monitoring levels over the 24 hours after each experimental condition
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Glycaemic variability (standard deviation)
Standard deviation (SD) of the mean continuous glucose monitoring levels over the 24 hours after each experimental condition
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Glycaemic variability (coefficient of variation)
Coefficient of variation of glucose levels over the 24 hours after each experimental condition
Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)
Glycaemic variability (coefficient of variation)
Coefficient of variation of glucose levels over the 24 hours after each experimental condition
Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)
Maternal glucose metabolism
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the glucose-insulin axis will be analysed (i.e., glucose, insulin, C-peptide and HbA1c).
Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)
Maternal glucose metabolism
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the glucose-insulin axis will be analysed (i.e., glucose, insulin, C-peptide and HbA1c).
Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)
Maternal lipid profile
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the lipid profile will be analysed (i.e., total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL-cholesterol, triglycerides and free fatty acids).
Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)
Maternal lipid profile
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the lipid profile will be analysed (i.e., total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL-cholesterol, triglycerides and free fatty acids).
Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)
Maternal inflammatory markers
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to inflammatory-immunological responses will be analysed (e.g., IL-6, IL-8, IL-1β, TNFα, C-reactive protein, IFNγ)
Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)
Maternal inflammatory markers
Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to inflammatory-immunological responses will be analysed (e.g., IL-6, IL-8, IL-1β, TNFα, C-reactive protein, IFNγ)
Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)
Placenta weight
Placenta weight (grams)
Time frame: assessed at birth - 30 minutes
Placenta biopsies
Eight biopsies will be collected, four on the maternal site and four on the fetal side. Relevant placental proteins (growth factors and cytokines) related to insulin signalling, glucose metabolism, and inflammation will be analysed (e.g., GM-CSF, GCSF, MCP1, TNF-α, IL-6, EGF, IFN-γ, IL-8, IL-10, IL-1β).
Time frame: collected at birth - 1 hour
Neonate weight
Neonate weight (grams)
Time frame: assessed at birth - 5 minutes
Placenta efficiency
Neonate weight divided by placenta weight
Time frame: estimated after birth - 3 minutes
Placenta completeness
The number of present and missing cotyledons and velamentous vessels will be examined visually in all the quadrants.
Time frame: assessed at birth - 20 minutes
Neonate height
Neonate height (cm)
Time frame: assessed at birth - 5 minutes
Neonate ponderal index
Neonate weight/height ratio: 100 x weight / (Height)3
Time frame: estimated after birth - 3 minutes
Neonate anthropometrics
Neonate head and abdomen circumference (cm). These circumferences will be measured using a stretch-resistant measuring tape.
Time frame: assessed at birth - 10 minutes
Neonate Apgar score
Neonate Apgar score (1-10). The higher score is indicative of a better health status of the newborn after birth
Time frame: assessed at birth - 5 minutes
Small for gestational age
Newborns will be diagnosed as small for gestational age newborns if their birth weight is lower than the 10th percentile for their gestational age
Time frame: assessed after birth - 5 minutes
Large for gestational age
Newborns will be diagnosed as large for gestational age newborns if their birth weight is greater than the 90th percentile for their gestational age
Time frame: assessed after birth - 5 minutes
Physical fitness (muscle strenght)
Upper body muscle strength will be measured by the handgrip strength test.
Time frame: assessed in the phase 1, at visit nº 1 (10 minutes)
Physical fitness (muscle strenght)
Upper body muscle strength will be measured by the handgrip strength test.
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (10 minutes)
Physical fitness (flexibility)
Upper body flexibility will be assessed by the back scratch test, measuring the distance or overlap between the middle fingers of both hands behind the back.
Time frame: assessed in the phase 1, at visit nº 1 (10 minutes)
Physical fitness (flexibility)
Upper body flexibility will be assessed by the back scratch test, measuring the distance or overlap between the middle fingers of both hands behind the back.
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (10 minutes)
Physical fitness (cardiorespiratory fitness)
Cardiorespiratory fitness will be assessed using a submaximal walking treadmill test while recording gas exchange data (breath by breath system).
Time frame: assessed in the phase 1, at visit nº 1 (30 minutes)
Physical fitness (cardiorespiratory fitness)
Cardiorespiratory fitness will be assessed using a submaximal walking treadmill test while recording gas exchange data (breath by breath system).
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (30 minutes)
Resting energy expenditure
Gas exchange will be measured breath by breath using a portable gas analyser
Time frame: assessed in the phase 1, at visit nº 1 (2 hours)
Physical activity
Physical activity levels will be measured with triaxial accelerometry.
Time frame: assessed in the phase 1 - 10 continuous days
Physical activity
Physical activity levels will be measured with triaxial accelerometry.
Time frame: assessed in the phase 2 (only pregnant women) - 10 continuous days
Vital signs (systolic and diastolic blood pressure)
Systolic and diastolic blood pressure (mmHg) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.
Time frame: assessed in the phase 1, at visit nº 1 (15 minutes)
Vital signs (systolic and diastolic blood pressure)
Systolic and diastolic blood pressure (mmHg) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (15 minutes)
Vital signs (resting heart rate)
Resting heart rate (beats per minute) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.
Time frame: assessed in the phase 1, at visit nº 1 (15 minutes)
Vital signs (resting heart rate)
Resting heart rate (beats per minute) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (15 minutes)
Initial anamnesis (sociodemographic and clinical information)
Relevant information from the patients will be collected by the physicians who will ask them, and by an initial questionnaire prepared by the researchers (e.g., age, educational level, occupational status, medications, diseases, etc.).
Time frame: assessed in the phase 1, at visit nº 1 (40 minutes)
Sleep quality (questionnaire)
The sleep quality will be assessed using a validated questionnaire, the Pittsburgh Sleep Quality Index questionnaire (PSQI). Higher scores indicate worse sleep quality (0-21).
Time frame: assessed in the phase 1, at visit nº 1 (20 minutes)
Sleep quality (questionnaire)
The sleep quality will be assessed using a validated questionnaire, the Pittsburgh Sleep Quality Index questionnaire (PSQI). Higher scores indicate worse sleep quality (0-21).
Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (20minutes)
Ran from Jun 2023 to primary completion in Sep 2025, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Graz